Introduction
============

Since the discovery of the epidermal growth factor receptor (*EGFR*) mutation in 2004, personalized treatment based on genomic variations has significantly changed lung cancer clinical practice in the past 10 years. EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib have opened the gate of precise medicine and become a standard therapy for patients with non-small-cell lung cancer (NSCLC) harboring the *EGFR* mutation. EGFR inhibitors came first and then target driver gene was discovered. Conversely, the anaplastic lymphoma kinase (*ALK*) rearrangement in NSCLC was discovered prior to the development of an effective inhibitor. Thus, the development of the ALK inhibitor crizotinib became a typical model in personalized lung cancer treatment. The first clinical trial of crizotinib, PROFILE 1001,[@b1-ott-8-999] was conducted for unselected patients with solid tumors in 2007. During the same year, *ALK* rearrangement was also first reported and a diagnostic fluorescence in situ hybridization (FISH) assay was developed for NSCLC. Fortunately, two NSCLC *ALK*-positive patients were enrolled in this Phase I trial and experienced a significant disease control. Subsequently, crizotinib was widely used in *ALK*-positive lung cancer patients. Only 4 years later in 2011, crizotinib was approved by the US Food and Drug Administration, a relatively short period from laboratory to market.

Crizotinib was approved by the Chinese Food and Drug Administration for *ALK*-positive patients in any line setting in 2013. It was only based on results of PROFILE 1001, 1005,[@b2-ott-8-999] and 1007,[@b3-ott-8-999] when the mature results of PROFILE 1014[@b4-ott-8-999] and 1029[@b5-ott-8-999] were not available. The crizotinib was not covered by the Chinese health insurance system, and most patients could not tolerate the financial burden. The charitable project of crizotinib in People's Republic of China was started in April 2014. Chinese mainland citizens over 18 years of age with low income could apply for free crizotinib if they paid for the drug during the initial 4 months of treatment. The reduced economical burden greatly enhances patient adherence. To date, more than 3,000 Chinese *ALK*-positive patients have taken crizotinib in this charitable project (internal data provided by Pfizer). This review focused on the role of crizotinib in personalized treatment in People's Republic of China.

Pharmacology, mode of action, and pharmacokinetics of crizotinib
================================================================

Crizotinib (PF-02341066) is a potent and selective small- molecule inhibitor of MET kinase,[@b6-ott-8-999] ALK,[@b7-ott-8-999],[@b8-ott-8-999] and ROS.[@b9-ott-8-999] Crizotinib competes with ATP for binding to the catalytic pocket, which inhibits the receptor tyrosine kinase downstream signaling pathways that are critical for growth and survival.

The pharmacokinetics of crizotinib were assessed in 15 Chinese patients (seven males and eight females) with advanced *ALK*-positive NSCLC who were enrolled in PROFILE 1005.[@b10-ott-8-999] The median time for crizotinib to achieve peak concentration was 4--6 hours after absorption, which was similar to the first 80 patients of various ethnicities enrolled in PROFILE 1001.[@b1-ott-8-999] The mean *C*~max~ of crizotinib was 117 ng/mL and AUC~inf~ was 2,711 ng h/mL. Following attainment of *C*~max~, plasma concentrations of crizotinib declined in a multi-exponential manner with an average half-life terminal elimination of approximately 39 hours, which was slightly shorter than that in the 80 patients mentioned earlier, whose average terminal half-life was 43--51 hours. The plasma concentrations of crizotinib reached a steady state within 15 days and increased with a median accumulation ratio of 5.2 days. The geometric mean values for the apparent clearance were 57.7 L/h and 59.7 L/h, following 15 and 29 days of dosing, respectively, which were lower than those observed after a single dose (92.3 L/h), indicating that crizotinib exhibited nonlinear pharmacokinetics due to autoinhibition of CYP3A4.

Compared with non-Asian patients, Asian patients had higher crizotinib exposure. A comparison study evaluated crizotinib pharmacokinetics in 95 patients, including 32 Asian and 63 non-Asian patients, with advanced malignancies.[@b11-ott-8-999] The mean AUCtau-ss and *C*max-ss were, respectively, 56% and 70% higher in Asian than in non-Asian patients (body weight adjustment accounted for 30% of the difference) after repeated crizotinib, with median trough concentrations 41%--59% (median 50%) higher. An analysis of 167 patients from PROFILE 1001 included 42 Asian and 125 non-Asian patients and showed that mean values for crizotinib *C*~max~ and AUC in Asian patients were 1.57-fold (90% confidence interval, 1.16--2.13) and 1.50-fold (90% confidence interval, 1.10--2.04) those seen in non-Asian patients, respectively.[@b12-ott-8-999] Another analysis included 8,973 pharmacokinetic samples from 1,214 patients treated with crizotinib in Phase I, II, and III trials; 43.1% were Asian patients.[@b13-ott-8-999] The AUC~ss~ in Asian patients were over 25% higher than typical AUC~ss~ values in non-Asian patients.

Diagnosis of *ALK* rearrangements in People's Republic of China
===============================================================

The prevalence of *ALK* rearrangements is 3.3%--11.6% in Chinese patients[@b14-ott-8-999]--[@b16-ott-8-999] similar to other Asian patients,[@b17-ott-8-999],[@b18-ott-8-999] slightly greater than that in non-Asian patients.[@b18-ott-8-999],[@b19-ott-8-999] and much lower than EGFR mutations -- about 30% in Chinese patients.[@b16-ott-8-999] Currently, three major methods are used for the detection of *ALK* rearrangements in lung cancer; ie, break-apart FISH, Ventana immunohistochemistry (IHC), and polymerase chain reaction (PCR). All three methods were recommended by Chinese expert consensus opinion[@b20-ott-8-999] and approved as companion diagnostic tests by the Chinese Food and Drug Administration, which is quite different from other guidelines developed in the US and EU.

FISH is the standard method for the detection of *ALK* rearrangements in lung cancer globally. However, the application of FISH was restricted mainly by its cost-effectiveness and the lack of experienced pathologists in People's Republic of China.

IHC is much more rapid and affordable. Ventana IHC was developed by Roche for detecting *ALK* rearrangements. The sensitivity and specificity of Ventana IHC are 100% and 99%, respectively,[@b21-ott-8-999]--[@b26-ott-8-999] as shown in [Table 1](#t1-ott-8-999){ref-type="table"}; thus, Chinese experts recommend the Ventana IHC as a diagnostic test for *ALK* rearrangements. This test has also been approved in Europe but still under consideration of National Comprehensive Cancer Network/College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines. A prospective observational trial of diagnosis of *ALK* rearrangements in unselected NSCLC patients using Ventana IHC in People's Republic of China was launched in 2013.[@b27-ott-8-999] The primary objective is to obtain epidemiological data in unselected Chinese patients with *ALK*-positive NSCLC. The estimated enrollment is 10,000, and 3,000 patients have been enrolled to date.

The reverse transcription (RT)-PCR method is the least subjective methodology for the detection of *ALK* rearrangements.[@b28-ott-8-999] However, it requires high-quality RNA or is unable to detect the unknown fusion partners.[@b15-ott-8-999],[@b23-ott-8-999],[@b29-ott-8-999]--[@b31-ott-8-999] RT-PCR is also recommended by the Japan Lung Cancer Society but not by the National Comprehensive Cancer Network or College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology guidelines. The three types of PCR recommended by Chinese expert consensus opinion include quantitative RT-PCR, rapid amplification of cDNA ends-coupled PCR sequencing, and specific primer-based RT-PCR coupling direct sequencing.[@b20-ott-8-999]

The three *ALK* detection methods have advantages and disadvantages, as mentioned earlier. However, both Ventana IHC and RT-PCR have high sensitivity and specificity compared with FISH ([Table 1](#t1-ott-8-999){ref-type="table"}). The methods used by clinicians in People's Republic of China to detect *ALK* arrangements differ according to the equipment available. The *ALK* test procedures used in People's Republic of China are shown in [Figure 1](#f1-ott-8-999){ref-type="fig"}.

Efficacy of crizotinib in *ALK*-positive patients
=================================================

The efficacy and safety of crizotinib were confirmed through a series of clinical trials named PROFILE ([Table 2](#t2-ott-8-999){ref-type="table"}). PROFILE 1001 is a Phase I dose-escalation trial that was the first to find a target population with *ALK*-positive and embedded biomarker in patient's selection in the early stage of drug development. PROFILE 1005 is a Phase II trial that selected patients with *ALK* rearrangements to evaluate the efficacy and safety of crizotinib. Based on the results of these two trials, *ALK* rearrangement was defined as a definitive target biomarker. Subsequent Phase III trials, either second line (PROFILE 1007) or first line (PROFILE 1014 and PROFILE 1029), were based on biomarker selection. The results are shown in [Table 3](#t3-ott-8-999){ref-type="table"}. All PROFILE trials showed good consistency; higher objective response rate (ORR), longer progression-free survival (PFS), overall survival, and better safety compared to chemotherapy; these are the characteristics of precise cancer treatment.

Asian patients accounted for 28%--46% of the overall population in the PROFILE series ([Table 3](#t3-ott-8-999){ref-type="table"}).[@b2-ott-8-999]--[@b4-ott-8-999],[@b32-ott-8-999] Asian patients had higher response rates than non-Asian patients, possibly related to the higher crizotinib exposure. Twenty-three Chinese patients were enrolled in PROFILE 1005 and 1007. The ORR was 73.9%,[@b33-ott-8-999] similar to that in Asian patients but higher than in non-Asian patients.

Although ORR was higher in Asian patients, the PFS was similar among ethnicities, as shown in [Table 3](#t3-ott-8-999){ref-type="table"}. The median PFS of the 23 Chinese patients enrolled in PROFILE 1005 and 1007 was 7.0 months.[@b32-ott-8-999] Several retrospective analyses of Chinese patients reported median PFS of 6.0--7.6 months.[@b34-ott-8-999]

Safety and tolerability of crizotinib
=====================================

The normal *ALK* function in adult humans is unknown, but it is involved in gut development[@b35-ott-8-999] and retinal axon targeting[@b36-ott-8-999] in *Drosophila*. Therefore, the predominant adverse events (AEs) of crizotinib were visual effects and gastrointestinal events, which may represent on-target anti-*ALK* effects. The AEs of 1,255 patients taking crizotinib in three trials (PROFILE 1001, 1005, and 1007) were analyzed.[@b37-ott-8-999] The most common gastrointestinal events were nausea (49%), diarrhea (44%), vomiting (41%), and constipation (29%). The incidence of visual impairment was 42%. Most AEs mentioned earlier were grade 1--2 in severity, which was similar to other reports and our clinical experience in Chinese patients.[@b34-ott-8-999],[@b38-ott-8-999]--[@b40-ott-8-999] The most common treatment-related grade 3/4 AEs were neutropenia (7%) and elevated alanine aminotransferase (ALT) (6%) and aspartate aminotransferase (AST) (\<3%) levels. Among the AE grades, neutropenia and elevated ALT and AST levels occurred in 11%, 21%, and 15% patients, respectively.[@b37-ott-8-999],[@b38-ott-8-999],[@b41-ott-8-999]

The incidence of AEs based on ethnicity differs slightly. The incidence of AEs was higher in non-Asian patients compared with Asian patients in the subgroup analysis of 901 patients enrolled in PROFILE 1005.[@b42-ott-8-999] An analysis of 95 patients (32 non-Asian and 63 Asian patients) with advanced malignancies taking crizotinib showed that Asian patients had a higher incidence of low-grade AEs (eg, gastrointestinal, visual impairment) but a lower incidence of high-grade AEs (eg, increased ALT).[@b11-ott-8-999] The treatment-related grade 3 and/or 4 AEs occurred in 2.4% (9/379) and 6.7% (35/522) and grade 5 serious AEs in 1.1% \[4/379\] and 1.3% \[7/522\] of Asian and non-Asian patients, respectively. Due to AEs, 12% of Asian patients and 18% of non-Asian patients discontinued their treatment. In another pooled analysis of 1,053 patients from PROFILE 1005 and 1007, Asian patients were less susceptible to sinus bradycardia compared with non-Asian patients (*P*=0.039),[@b43-ott-8-999] indicating that crizotinib was slightly safer in Asian patients.

Overcoming resistance to crizotinib
===================================

Nearly all patients develop resistance to crizotinib. The mechanism of resistance includes secondary mutations in the tyrosine kinase domain of *ALK, ALK* copy number gain, the aberrant activation of other driver genes, and several unknown mechanisms.[@b44-ott-8-999],[@b45-ott-8-999]

The second-generation ALK TKIs, such as ceritinib (LDK378),[@b46-ott-8-999] alectinib (RO5424802),[@b47-ott-8-999] and AP26113,[@b48-ott-8-999] showed strong capability in patients resistant to crizotinib. Ceritinib was approved by the US Food and Drug Administration in early 2014 and alectinib has been approved by the Japanese government.

In addition to novel drugs, National Comprehensive Cancer Network guidelines recommended new strategies for patients resistant to crizotinib according to response evaluation criteria in solid tumors criteria. Patients with asymptomatic progression can continue taking crizotinib. The patients with symptomatic progression in the brain or an isolated extracranial lesion can receive local treatment and continue taking crizotinib. Patients with symptomatic progression in multiple lesions can change to chemotherapy. An analysis of 194 patients from PROFILE 1005 and 1007 was conducted; 120 (62%) patients continued taking crizotinib beyond disease progression because the investigators believed that ongoing clinical benefits could be obtained. The patients who continued taking crizotinib had significantly longer overall survival from the time of progressive disease (median 16.4 months vs 3.9 months; hazard ratio, 0.27; *P*,0.0001).[@b49-ott-8-999]

Basket trial: crizotinib in different tumors
============================================

An increasing number of driver genes are being discovered in solid tumors, including NSCLCs. Based on different driver genes, NSCLC was subdivided in different rare diseases. Innovative clinical trials have been performed, including basket trials. The basket trial is defined as testing of one drug against the same genetic abnormality in different organs. The *ALK* abnormality has been discovered in many solid tumors, including anaplastic large-cell lymphoma,[@b50-ott-8-999] inflammatory myofibroblastic tumor,[@b51-ott-8-999] diffuse large B-cell lymphoma,[@b52-ott-8-999] esophageal squamous cell carcinoma,[@b53-ott-8-999] and several other tumors.[@b54-ott-8-999],[@b55-ott-8-999] Tumors originating from various organs carrying abnormal *ALK* as an essential growth driver were defined as "*ALK* oma".[@b56-ott-8-999] Crizotinib appears to be effective against tumors originating from various organs that harbor *ALK* abnormalities.[@b57-ott-8-999],[@b58-ott-8-999] There is an ongoing basket clinical trial (A8081013, [ClinicalTrials.gov](http://ClinicalTrials.gov) identifier NCT01121588) evaluating the safety and clinical activity of crizotinib in patients with *ALK*-positive malignancies other than NSCLC. There is no basket trial of crizotinib in People's Republic of China so far. In future, tumors could be classified based on genetic information beyond organs, such as *EGFR* oma and *RAF* oma and a single compound could be used for many cancer types in different organs. Similar to *ALK* oma cancers, *EGFR* oma and *RAF* oma cancers could be treated using EGFR TKIs and RAF TKIs.

Umbrella trail: crizotinib in lung cancers with different genetic abnormalities
===============================================================================

The umbrella trial is another innovative clinical trial in which several drugs are tested against multiple genetic abnormalities within one type of tumor, such as lung cancer. Crizotinib showed antitumor activities in lung cancer patients with *c-Met* or *ROS1* abnormalities and is particularly suitable for an umbrella trial.

Crizotinib in patients with *ROS1* rearrangements
=================================================

*ROS1* rearrangement was discovered in NSCLC in 2007.[@b59-ott-8-999] The researchers detected the activation of oncogenic kinases in 41 NSCLC cell lines and over 150 Chinese NSCLC patients using a phosphoproteomic approach. ROS was identified to have high tyrosine kinase phosphorylation in the HCC78 cell line and one patient tumor sample.

The frequency of *ROS1* was approximately 1.0%--2.0% in Chinese patients,[@b60-ott-8-999],[@b61-ott-8-999] similar to other ethnicities.[@b62-ott-8-999],[@b63-ott-8-999] However, the frequency of *ROS1* rearrangements in the triple-negative (without *EGFR/KRAS* mutations or *ALK* rearrangements) population was 8.2%, higher than that in the nonselected population.[@b64-ott-8-999]

Shaw et al[@b65-ott-8-999] reported the results of 50 patients with advanced NSCLC who tested positive for *ROS1* rearrangement in an expansion cohort of the PROFILE 1001. The AEs of crizotinib were similar to those in NSCLC patients with *ALK* rearrangements. The efficacy of crizotinib was better in patients with *ROS1* rearrangements than with *ALK* rearrangements. The ORR was 72%, including three complete responses. The median PFS was 19.2 months. One ROS1 trial in Asian patients is ongoing ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01945021).

Crizotinib in patients with de novo *c-Met* abnormalities
=========================================================

Preliminary results on the safety and efficacy of crizotinib in NSCLC patients with *c-Met* amplification were reported in the 2014 American Society of Clinical Oncology, which was part of the ongoing Phase I trial (A8081001, ClinicalTrials. gov identifier: NCT00585195).[@b40-ott-8-999] The *c-Met* amplification status was divided into the following four categories: negative (MET/CEP7 ratio ≤1.8), low (MET/CEP7 ratio ≥ 1.8 to ≤ 2.2), intermediate (\>2.2 to \<5) and high (≥ 5). CEP7 refers to the chromosome 7 centromere. At data cutoff, 13 patients with amplified *c-Met* were treated with crizotinib. The median duration of response was 35 weeks (95% confidence interval, 16--112). The AEs were similar to crizotinib in *ALK*-positive patients; most were grade 1 in severity. The antitumor activity and general tolerability of crizotinib were first indicated in a prospective clinical trial.

De novo c-Met expression was detected using IHC in NSCLC patients in Guangdong Lung Cancer Institute in People's Republic of China.[@b66-ott-8-999],[@b67-ott-8-999] c-Met overexpression was defined as more than 50% tumor cells with moderate- to high-intensity staining. Thirteen patients with c-Met overexpression treated with crizotinib were evaluable for response; six experienced partial response (PR), two stable disease, and five progressive disease. One patient died of interstitial lung disease attributed to crizotinib, suggesting that c-Met overexpression could be a predictive factor of crizotinib.

De novo c-Met overexpressions/amplifications coexisting with *EGFR* mutations, *KRAS* mutations, and *ALK* rearrangements were analyzed in Guangdong Lung Cancer Institute in People's Republic of China. The definition of overexpression was as mentioned earlier and amplification was detected using FISH.[@b68-ott-8-999] Seven patients with concomitant de novo c-Met overexpression and *EGFR* mutations received first-line EGFR TKIs. The ORR was 71.4% (5/7). One patient with concomitant de novo c-Met overexpression and *EGFR* mutations developed intrinsic resistance to first-line crizotinib. Five patients with concomitant de novo c-Met overexpressions and *ALK* rearrangements received crizotinib, and the response rate was 80%. The patient with concomitant de novo c-Met overexpression and *KRAS* mutation was resistant to crizotinib. Based on these results, NSCLC patients with concomitant de novo c-Met overexpression and other driver genes can have diverse responses to TKIs, which may depend on the predominant pathway in the tumor.[@b69-ott-8-999],[@b70-ott-8-999]

Crizotinib in patients with acquired c-Met abnormalities
========================================================

*c-Met* amplification was found in 13%--33% of patients with acquired resistance to EGFR TKIs[@b71-ott-8-999],[@b72-ott-8-999] and is the second most common EGFR TKIs resistance mechanism, following the T790M mutation. The sensitivity to EGFR TKIs was restored by the inhibition of c-Met signaling in a gefitinib-resistant HCC827 cell line.[@b73-ott-8-999]

Patients with acquired resistance to EGFR TKIs were enrolled in a Phase I trial ([ClinicalTrials.gov](http://ClinicalTrials.gov) identifier: NCT01121575) to receive dacomitinib combined with crizotinib. The preliminary results showed that toxicity was manageable and the clinical activity was promising.[@b74-ott-8-999] A retrospective analysis of 80 advanced NSCLC patients with acquired resistance to first-line EGFR TKIs from People's Republic of China was conducted. Twenty-three of the 80 patients (28.8%) had *c-Met* amplifications, including four patients taking crizotinib after resistance to EGFR TKIs. Among the three patients treated with crizotinib plus gefitinib, two attained PR and one attained stable disease.[@b72-ott-8-999],[@b75-ott-8-999]

The preclinical and clinical data showed that *c-Met*-positive patients would benefit from crizotinib or crizotinib combined with EGFR TKIs and exhibit good tolerance. The major challenge when prescribing crizotinib to *c-Met*-positive patients is defining which *c-Met* state is predictive of the effect of crizotinib: c-Met amplification, overexpression, or mutation, and defining the standard detection methods and standard cutoff value of each method.

Conclusion
==========

Crizotinib has played an important role in the development of precise treatments due to its unique antitumor PROFILE. Crizotinib is efficacious in Chinese NSCLC patients with *ALK* rearrangements and its toxicity is manageable. The application of crizotinib in Chinese *c-Met/ROS1*-positive NSCLC patients is promising but prospective clinical trials are required to confirm its efficacy and safety. *ALK/c-Met/ROS1*-positive patients account for approximately 10% of lung cancer cases, meaning about 10% lung cancer patients could benefit from crizotinib. The major challenge for prescribing crizotinib in clinical practice is establishing convenient diagnostic techniques for the detection of *ALK/c-Met/ROS1*. This review of crizotinib provides a reference for integrating genetic information in the classification of lung cancer and other tumors in the near future. Cancers might be classified as *ALK* oma, *EGFR* oma, and *RAF* oma and treated with ALK TKIs, EGFR TKIs, and RAF TKIs, respectively.
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![*ALK* testing procedures used in the People's Republic of China.\
**Abbreviations:** NSCLC, non-small-cell lung cancer; FFPE, formalin-fixed paraffin-embedded; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase chain reaction; FISH, fluorescence in situ hybridization.](ott-8-999Fig1){#f1-ott-8-999}

###### 

The sensitivity and specificity of Ventana IHC and PCR compared with FISH

  Reference                             Ventana IHC   PCR           
  ------------------------------------- ------------- ------ ------ -----
  Ying et al[@b21-ott-8-999]            100           98     98     95
  Demidova et al[@b22-ott-8-999]        100           100    88     100
  Wang et al[@b23-ott-8-999]            100           98.2   95.5   87
  Mino-Kenudson et al[@b24-ott-8-999]   100           99     --     --
  Minca et al[@b25-ott-8-999]           100           100    --     --
  Wynes et al[@b26-ott-8-999]           90            96     --     --

**Note:** --, the data were not provided in the article.

**Abbreviations:** FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; PCR, polymerase chain reaction.

###### 

The designs of PROFILE 1001, 1005, 1007, 1014, and 1029

  NCT identifier   Other ID numbers   Phase   Line       Population   Chinese included or not   Target             Convention
  ---------------- ------------------ ------- ---------- ------------ ------------------------- ------------------ ------------------------------------
  NCT00585195      PROFILE 1001       I       Any line   Global       No                        *ALK/c-Met/ROS1*   Crizotinib
  NCT00932451      PROFILE 1005       II      ≥2         Global       Yes                       *ALK*              Crizotinib
  NCT00932893      PROFILE 1007       III     2          Global       Yes                       *ALK*              Crizotinib vs pemetrexed/docetaxel
  NCT01154140      PROFILE 1014       III     1          Global       Yes                       *ALK*              Crizotinib vs PC/PP
  NCT01639001      PROFILE 1029       III     1          East Asian   Yes                       *ALK*              Crizotinib vs PC/PP

**Abbreviations:** PC, pemetrexed plus carboplatin; PP, pemetrexed plus cisplatin.

###### 

The efficacy of crizotinib in Asian and non-Asian populations

  ID Numbers                     Number of patients   ORR (%)    PFS (months)                                            
  ------------------------------ -------------------- ---------- -------------- ------ ------ ------ ------ ----- ------ ----
  PROFILE 1001[@b32-ott-8-999]   149                  41 (28)    60.8           54.8   76.9   --     9.7    --    --     --
  PROFILE 1005[@b2-ott-8-999]    259                  93 (36)    59.8           54     70     73.9   8.1    --    --     7
  PROFILE 1007[@b3-ott-8-999]    347                  157 (45)   65             --     75     --     7.7    7.1   8.1    --
  PROFILE 1014[@b4-ott-8-999]    343                  157 (46)   74             72     70     --     10.9   --    13.6   --

**Note:** --, the data were not available.

**Abbreviations:** ORR, objective response rate; PFS, progression-free survival.
